Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody.
An active vaccination protocol was performed on one patient with colon carcinoma as a pilot to a prospective randomized double-blind clinical trial with the vaccine SDZ SCV 106. This vaccine is an anti-idiotype goat antibody to the monoclonal antibody 17-1A, which is directed against the tumor antigen 17-1A. To study the effect of the therapy on the immune reactivity, several tests were performed to detect anti-tumor antibodies in the serum as well as in eluates of metastatic tissue. Furthermore metastases removed from the lung were examined by immunohistochemistry. The results suggest that the humoral and cellular immune reactivity against the tumor are enhanced.
Samonigg
H
H
Department of Internal Medicine, Karl Franzens University, Graz, Austria.
Wilders-Truschnig
M
M
Loibner
H
H
Plot
R
R
Rot
A
A
Kuss
I
I
Werner
G
G
Stöger
H
H
Wrann
M
M
Herlyn
D
D
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009362:Neoplasm Metastasis; D010865:Pilot Projects; D014611:Vaccination
D000888:Antibodies, Anti-Idiotypic; D000912:Antibodies, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate